Company Profile

Psycheceutical Bioscience, Inc. is a bioscience company engaged in developing technologies to advance the delivery of psychedelic pharmaceutical medicines. The Companyâ€™s patented NeuroDirect non-systemic delivery technology is designed to deliver neuro-active compounds directly into the nerve tissue via topical application at the back of the neck. The delivery system is intended to enable immediate and sustained delivery, safe dosage control, and consistent results-while avoiding the GI tract and any unwanted side effects and toxicity. It has designed a product that improves the quality of life for those suffering from Post-Traumatic Stress Disorder (PTSD) and Chronic Regional Pain Syndrome (CRPS). Its pipeline program includes the PSY-007-KETAMINE. It focuses on commercializing its precision dosing technologies to provide affordable, life-saving treatments to anyone suffering from mental health disorders or central nervous system diseases.

Employees

Sector

Biotechnology & Medical Research

More about the company

20/06/24	Blue Water Ventures International, Inc. announced that it expects to receive $10 million in funding	CI
12/12/23	Psycheceutical Bioscience, Inc. Announces Chief Executive Officer Changes	CI

20/06/24	Blue Water Ventures International, Inc. announced that it expects to receive $10 million in funding	CI
12/12/23	Psycheceutical Bioscience, Inc. Announces Chief Executive Officer Changes	CI
12/12/23	Psycheceutical Bioscience, Inc. Appoints Neilank K. Jha as Its New Executive Chairman	CI
26/09/23	Blue Water Ventures International, Inc. announced that it expects to receive $5 million in funding	CI
13/07/23	Psycheceutical Bioscience, Inc Announces First Patient Has Been Dosed in Its Phase I Study to Evaluate Its Patented Neurodirectâ„¢ Ketamine Topical Delivery System for the Treatment of Post Traumatic Stress Disorder	CI
21/03/23	Psycheceutical Bioscience, Inc. Announces Publication of Pre-Clinical Observational Data Supports Potential of its NeuroDirect™ Ketamine Topical Cream as Treatment for PTSD	CI
15/02/23	Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD	CI
01/03/22	Blue Water Ventures International, Inc. announced a financing transaction	CI
17/02/22	Blue Water Ventures International, Inc. announced that it has received $0.771 million in funding	CI
29/01/22	Blue Water Ventures International, Inc. announced that it expects to receive $0.771 million in funding	CI
20/01/22	Blue Water Ventures International, Inc. completed the acquisition of Psycheceutical, Inc.	CI
03/11/21	Blue Water Ventures International, Inc. signed a non-binding letter of intent to acquire Psycheceutical, Inc.	CI
17/03/21	Blue Water Ventures International Signs Extension on Pulaski Recovery	CI

05-16	Maha and BWIV terminate the Letter of Intent for proposed SPAC transaction	AQ
01/10/25	Blue Water pitches $10bn offer for Citgo in Delaware court	AQ
16/09/25	Delaware court opens Venezuela’s Citgo sale battle as creditors vie for control	AQ
09/09/25	Blue Water bids $10bn for Venezuela’s Citgo, offers bondholders cash and equity	AQ
08/09/25	Blue Water Acquisition Corp. III Announces Submission of $10 Billion Bid for PDV Holding Inc., Parent of Citgo Petroleum Corp.	AQ

Manager	Title	Age	Since
Neilank K. Jha CEO	Chief Executive Officer	-	12/12/2023
Michael Hlavsa DFI	Director of Finance/CFO	72	-
Julian Bailes CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Bruce Cassidy BRD	Director/Board Member	75	-
Michael Gurin BRD	Director/Board Member	-	-
Michael Hlavsa BRD	Director/Board Member	72	-

Blue Water Ventures International Inc Stock Other OTC

Stocks

US8317182009

Biotechnology & Medical Research

Latest news : Blue Water Ventures International Inc

Press Releases: Blue Water Ventures International Inc

Managers and Directors: Blue Water Ventures International Inc

Other Biotechnology & Medical Research

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	-4.89%	-7.74%	-3.35%	+9.27%	48.5B
REVOLUTION MEDICINES, INC.	-0.14%	-0.76%	+378.26%	+583.71%	38.97B
BEONE MEDICINES AG	+0.39%	+2.79%	+8.23%	+61.99%	35.43B
IQVIA HOLDINGS INC.	-1.54%	-4.01%	+5.95%	-13.03%	33.65B
CELLTRION, INC.	-0.87%	-3.19%	-1.27%	+29.16%	26.58B
ASCENDIS PHARMA A/S	-1.28%	-6.20%	-	-	16.82B
MEDPACE HOLDINGS, INC.	-0.67%	-0.21%	+10.55%	+115.31%	15.18B
EUROFINS SCIENTIFIC SE	+1.32%	+1.85%	+11.40%	+15.52%	13.89B
ICON PUBLIC LIMITED COMPANY	+0.40%	-2.79%	+3.58%	-31.98%	12.76B
Average	-0.81%	-1.76%	+51.67%	+96.24%	26.87B
Weighted average by Cap.	-1.29%	-1.77%	+68.45%	+121.29%

End-of-day quote Other OTC Other stock markets
- ^USD	-